WAT

Waters Corporation (WAT) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended April 4, 2026. The quarter is dominated by the completion of the BDS Business Acquisition (Biosciences & Diagnostic Solutions business of Becton, Dickinson and Company) on February 9, 2026. The transaction was structured as a Reverse Morris Trust, resulting in the issuance of approximately 38.5 million shares of Waters common stock to BD shareholders. Consequently, the company reorganized its reporting into three segments: Analytical & Materials Sciences, Biosciences, and Advanced Diagnostics. Results for the BDS Business are included from the closing date forward.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 91% year-over-year. This was primarily driven by $520 million in revenue from the BDS Business post-closing. Excluding BDS, legacy revenue grew 13%.
• Profitability Decline: The company reported an operating loss of $47 million compared to $152 million in income the prior year. This reversal is attributed to significant non-recurring and acquisition-related costs, including:
  • $140 million in purchased intangibles amortization.
  • $99 million in acquisition-related inventory and fixed asset fair value step-up expenses.
  • $83 million in transaction, integration, and internal costs related to the BDS acquisition.
  • Increased interest expense due to debt financing for the acquisition.
• Balance Sheet Expansion: Total assets increased from $5.1 billion to $24.5 billion, and total liabilities rose from $2.5 billion to $9.2 billion, reflecting the consolidation of the BDS Business. Goodwill increased by approximately $8.0 billion.
• Debt Structure: To fund the acquisition, the company issued $3.5 billion in Senior Notes and assumed $4.0 billion in term loans (SpinCo Credit Agreement), though $3.5 billion of the term loan was repaid using the Senior Notes proceeds.

Guidance, Outlook, and Risks

• Outlook: Management notes that period-over-period comparability is materially impacted by the acquisition. Legacy business growth remains broad-based across product lines and regions. Foreign currency translation is expected to be neutral to gross profit for the full year 2026.
• Tariffs and Trade: The company faces uncertainty regarding U.S. tariffs and a recent Supreme Court decision invalidating tariffs under the International Emergency Economic Powers Act. While the company may be eligible for refunds, the timing and recoverability are uncertain. Retaliatory tariffs and supply chain disruptions remain risks.
• Integration Risks: Key risks include the ability to realize anticipated synergies, delays in integrating the BDS Business, and the successful transition of "Deferred Close Businesses" (assets in China and Italy not yet legally transferred).
• ERP Implementation: The company is implementing a new worldwide ERP system with an anticipated total cost of $130 million, of which $72 million has been spent through Q1 2026.

Investor Verification Checklist

• Acquisition Accounting: Verify the final purchase price allocation and the measurement period adjustments for the BDS Business, particularly regarding goodwill and intangible asset valuations.
• Deferred Close Businesses: Monitor the status of the legal transfer of assets in China and Italy, which are currently operated under an Interim Operating Agreement with BD.
• Debt Covenants: Confirm continued compliance with leverage and interest coverage ratios given the significant increase in debt load ($5.2 billion total).
• Tariff Refunds: Track the progress of potential tariff refunds following the Supreme Court ruling and their impact on future cost structures.
• Legacy Growth: Assess organic growth rates of the legacy Analytical & Materials Sciences segment excluding the impact of the BDS acquisition to gauge underlying business health.